Content
March 2024, Volume 8, Issue 2
- 147-170 Health Economic Evaluations of Hemochromatosis Screening and Treatment: A Systematic Review
by Malvina Hoxha & Visar Malaj & Bruno Zappacosta - 171-190 A Systematic Literature Review of Health-Related Quality of Life Outcomes and Associated Utility Values in Relapsed and/or Refractory Large B Cell Lymphoma
by Fei Fei Liu & Meaghan Bartlett & Samantha Craigie - 191-203 Artificial Intelligence to Automate Health Economic Modelling: A Case Study to Evaluate the Potential Application of Large Language Models
by Tim Reason & William Rawlinson & Julia Langham & Andy Gimblett & Bill Malcolm & Sven Klijn - 205-220 Artificial Intelligence to Automate Network Meta-Analyses: Four Case Studies to Evaluate the Potential Application of Large Language Models
by Tim Reason & Emma Benbow & Julia Langham & Andy Gimblett & Sven L. Klijn & Bill Malcolm - 221-233 The Efficiency of Increased HCV Testing and Treatment Strategies in Spain to Achieve Elimination Goals
by Jose Luis Calleja & Jaime Espin & Ankita Kaushik & Manuel Hernandez-Guerra & Rob Blissett & Alon Yehoshua & Adam Igloi-Nagy - 235-249 Cost-Utility Analysis of Total Ankle Replacement Compared with Ankle Arthrodesis for Patients Aged 50–85 Years with End-Stage Ankle Osteoarthritis: The TARVA Study
by Andrew J. Goldberg & Ekaterina Bordea & Kashfia Chowdhury & Iva Hauptmannova & James Blackstone & Deirdre Brooking & Elizabeth L. Deane & Stephen Bendall & Andrew Bing & Chris Blundell & Sunil Dhar & Andrew Molloy & Steve Milner & Mike Karski & Steve Hepple & Malik Siddique & David T. Loveday & Viren Mishra & Paul Cooke & Paul Halliwell & David Townshend & Simon S. Skene & Caroline J. Doré - 251-261 From Indication-Based Pricing to Blended Approach: Evidence on the Price and Reimbursement Negotiation in Italy
by Elvio Emanuele Rossini & Carlotta Galeone & Chiara Lucchetti & Claudio Jommi - 263-276 Health State Utilities Associated with False-Positive Cancer Screening Results
by Louis S. Matza & Timothy A. Howell & Eric T. Fung & Sam M. Janes & Michael Seiden & Allan Hackshaw & Lincoln Nadauld & Hayley Karn & Karen C. Chung - 277-289 Cost-Effectiveness Analysis of Adjuvant Olaparib Versus Watch and Wait in the Treatment of Germline BRCA1/2-Mutated, High-Risk, HER2-Negative Early Breast Cancer in Sweden
by Maria Polyzoi & Mattias Ekman & Anja Reithmeier & Johanna Jacob & Emma Karlsson & Evelina Bertranou & Barbro Linderholm & Robert Hettle - 291-302 Cost-Effectiveness Analysis of Abrocitinib Compared with Other Systemic Treatments for Severe Atopic Dermatitis in Spain
by Rosa María Romero Jiménez & Pedro Herranz Pinto & Minia Campos Domínguez & Susana Aceituno Mata & Alba Bellmunt & Miriam Prades & Daniel Arumi & Irene Hernández-Martín & Valeria Herrera-Lasso & Noelia Llevat & Alfonso Lossada Juste & Francisco José Rebollo Laserna - 303-311 An Analysis of Uncertainties and Data Collection Agreements in the Cancer Drugs Fund
by Laura A. Trigg & Maxwell S. Barnish & Samuel Hayward & Naomi Shaw & Louise Crathorne & Brad Groves & John Spoors & Thomas Strong & G. J. Melendez-Torres & Caroline Farmer - 313-331 Economic Evaluation of a Personalized Nutrition Plan Based on Omic Sciences Versus a General Nutrition Plan in Adults with Overweight and Obesity: A Modeling Study Based on Trial Data in Denmark
by Milanne Maria Johanna Galekop & Carin Uyl-de Groot & William Ken Redekop - 333-343 Understanding the Natural History of Chronic Hepatitis D: Proposal of a Model for Cost-Effectiveness Studies
by Ankita Kaushik & Geoffrey Dusheiko & Chong Kim & Nathaniel J. Smith & Csilla Kinyik-Merena & Gian Luca Tanna & Robert J. Wong - 345-345 Correction: From Indication-Based Pricing to Blended Approach: Evidence on the Price and Reimbursement Negotiation in Italy
by Elvio Emanuele Rossini & Carlotta Galeone & Chiara Lucchetti & Claudio Jommi
January 2024, Volume 8, Issue 1
- 5-18 The Acceptance of Indirect Treatment Comparison Methods in Oncology by Health Technology Assessment Agencies in England, France, Germany, Italy, and Spain
by Bérengère Macabeo & Théophile Rotrou & Aurélie Millier & Clément François & Philippe Laramée - 19-30 Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial
by Laurent Fauchier & Nicolas Lamblin & Jean Tardu & Lucile Bellier & Harinala Groyer & Deborah Ittah & Julien Chollet & Stephan Linden & Pierre Levy - 31-47 Specialist Palliative Care and Health Care Costs at the End of Life
by Patricia Kenny & Dan Liu & Denzil Fiebig & Jane Hall & Jared Millican & Sanchia Aranda & Kees Gool & Philip Haywood - 49-63 United States Value Set for the Functional Assessment of Cancer Therapy-General Eight Dimensions (FACT-8D), a Cancer-Specific Preference-Based Quality of Life Instrument
by Madeleine T. King & D. A. Revicki & R. Norman & F. Müller & R.C. Viney & A. S. Pickard & D. Cella & J. W. Shaw - 65-78 Preferences for Living Arrangements in Dementia: A Discrete Choice Experiment
by Christian Speckemeier & Carina Abels & Klemens Höfer & Anja Niemann & Jürgen Wasem & Anke Walendzik & Silke Neusser - 79-89 Developing a Natural History Model for Duchenne Muscular Dystrophy
by Jonathan Broomfield & M. Hill & F. Chandler & M. J. Crowther & J. Godfrey & M. Guglieri & J. Hastie & J. Larkindale & J. Mumby-Croft & E. Reuben & F. Woodcock & K. R. Abrams - 91-101 Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland
by Andrea Favre-Bulle & Min Huang & Amin Haiderali & Arjun Bhadhuri - 103-114 Cost of Patients with Alzheimer’s Disease in Spain According to Disease Severity
by Laura Gómez Maldonado & Ricardo de Mora-Figueroa & Angélica López-Angarita & Paulina Maravilla-Herrera & María Merino - 115-118 Exploring the Influence of Health Insurance Plans on Biosimilar Adoption Rates
by Jeremy Costin & Morgane C. Mouslim & Mariana P. Socal & Antonio Trujillo - 119-131 Early Cost-Effectiveness Analysis of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer Patients with Limited Peritoneal Carcinomatosis
by Joost G. E. Verbeek & Karen Sluis & Marieke A. Vollebergh & Johanna W. Sandick & Wim H. Harten & Valesca P. Retèl - 133-146 Economic Burden of Delayed Diagnosis in Patients with Pulmonary Arterial Hypertension (PAH)
by Hilary M. DuBrock & Hayley D. Germack & Marjolaine Gauthier-Loiselle & Jörg Linder & Ambika Satija & Ameur M. Manceur & Martin Cloutier & Patrick Lefebvre & Sumeet Panjabi & Robert P. Frantz
November 2023, Volume 7, Issue 6
- 863-875 Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15
by Marty Chaplin & Rebecca Bresnahan & Nigel Fleeman & James Mahon & Rachel Houten & Sophie Beale & Angela Boland & Yenal Dundar & Ashley Marsden & Pinki Munot - 877-886 Characteristics and Quality Appraisal of the Economic Evaluations Done in Ethiopia: A Systematic Review
by Bereket Bahiru Tefera & Desalegn Getnet Demsie & Adane Yehualaw & Chernet Tafere & Kebede Feyisa & Malede Berihun Yismaw & Belayneh Kefale & Zewdu Yilma - 887-914 Cost-Effectiveness of Non-pharmacological Interventions for Mild Cognitive Impairment and Dementia: A Systematic Review of Economic Evaluations and a Review of Reviews
by Gillian Eaglestone & Evdoxia Gkaintatzi & Harmony Jiang & Charlotte Stoner & Rosana Pacella & Paul McCrone - 915-926 Trade-Offs between Vaccine Effectiveness and Vaccine Safety: Personal versus Policy Decisions
by Semra Ozdemir & Sean Ng & Vinh Anh Huynh & Axel Mühlbacher & Hiang Khoon Tan & Eric Andrew Finkelstein - 927-940 Hospital Resource Utilization and Costs in Patients with Heart Failure in France
by Frank Chemouni & Tiffany Chihiro Nishikawa & Harinala Groyer & Oumou Diaby & Julien Chollet & Deborah Ittah - 941-950 Retrospective Comparison of Survival Projections for CAR T-Cell Therapies in Large B-Cell Lymphoma
by Elisabeth F. P. Peterse & Elisabeth J. M. Verburg-Baltussen & Alexa Stewart & Fei Fei Liu & Christopher Parker & Maarten Treur & Bill Malcolm & Sven L. Klijn - 951-961 Budget Impact Analysis of Risperidone Use and Adverse Event Monitoring in Autism Spectrum Disorder in Brazil: Assessment of Theoretical Versus Real Data
by Luis Phillipe Nagem Lopes & Alexander Itria & Luciane Cruz Lopes - 963-974 The EQ-5D-3L Valuation Study in Pakistan
by Madeeha Malik & Ning Yan Gu & Azhar Hussain & Bram Roudijk & Fredrick Dermawan Purba - 975-985 Cost-Effectiveness of Recombinant Zoster Vaccine for the Prevention of Herpes Zoster in Hematopoietic Stem Cell Transplant Recipients and Other Immunocompromised Adults in the United States
by Ahmed Salem & Elizabeth M. La & Desmond Curran & Brandon J. Patterson & Justin Carrico & Stéphane Lorenc & Katherine A. Hicks & Sara Poston & Christopher F. Carpenter - 987-995 Estimating Cumulative Health Care Costs of Childhood and Adolescence Autism Spectrum Disorder in Ontario, Canada: A Population-Based Incident Cohort Study
by Claire Oliveira & Bryan Tanner - 997-1006 Real-World Cost Effectiveness of a Policy of KRAS Testing to Inform Cetuximab or Panitumumab for Third-Line Therapy of Metastatic Colorectal Cancer in British Columbia, Canada
by Reka E. Pataky & Stirling Bryan & Mohsen Sadatsafavi & Stuart Peacock & Dean A. Regier - 1007-1013 Model and Empirical Data-Based Cost-Utility Studies of Continuous Glucose Monitoring in Individuals with Type 1 Diabetes: A Protocol of a Systematic Review on Methodology and Quality
by L. A. Jong & X. Li & S. Emamipour & S. Werf & M. J. Postma & P. R. Dijk & T. L. Feenstra - 1015-1015 Correction: Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15
by Marty Chaplin & Rebecca Bresnahan & Nigel Fleeman & James Mahon & Rachel Houten & Sophie Beale & Angela Boland & Yenal Dundar & Ashley Marsden & Pinki Munot
September 2023, Volume 7, Issue 5
- 679-708 Cost Effectiveness of Different Platelet Preparation, Storage, Selection and Dosing Methods in Platelet Transfusion: A Systematic Review
by Jorien Laermans & Hans Van Remoortel & Hans Scheers & Bert Avau & Jørgen Georgsen & Susan Nahirniak & Nadine Shehata & Simon J. Stanworth & Emmy De Buck & Veerle Compernolle & Philippe Vandekerckhove - 709-722 Humanistic and Economic Burden of IgA Nephropathy: Systematic Literature Reviews and Narrative Synthesis
by Kenar D. Jhaveri & Mark E. Bensink & Martin Bunke & Jonathon A. Briggs & David M. W. Cork & Anushya Jeyabalan - 723-738 Health State Utility Values in Early-Stage Non-small Cell Lung Cancer: A Systematic Literature Review
by Nick Jovanoski & Seye Abogunrin & Danilo Maio & Rossela Belleli & Pollyanna Hudson & Sneha Bhadti & Libby G. Jones - 739-750 Cost-Effectiveness Analysis of Antimicrobial Prescribing in the Treatment of Clostridioides Difficile Infection in England
by Tom Bromilow & Hayden Holmes & Laura Coote & Sam Woods & Joshua Pink - 751-764 Healthcare Costs at the End of Life for Patients with Non-cancer Diseases and Cancer in Denmark
by Anne Høy Seemann Vestergaard & Lars Holger Ehlers & Mette Asbjoern Neergaard & Christian Fynbo Christiansen & Jan Brink Valentin & Søren Paaske Johnsen - 765-776 Mapping the World Health Organization Disability Assessment Schedule (WHODAS 2.0) onto SF-6D Using Swedish General Population Data
by Anna Philipson & Lars Hagberg & Liselotte Hermansson & Jan Karlsson & Emma Ohlsson-Nevo & Linda Ryen - 777-792 Cost-Effectiveness Analysis of Siltuximab for Australian Public Investment in the Rare Condition Idiopathic Multicentric Castleman Disease
by Francis Shupo & Keith R. Abrams & Zanfina Ademi & Grace Wayi-Wayi & Natasa Zibelnik & Matt Kirchmann & Carolyn Rutherford & Kelly Makarounas-Kirchmann - 793-809 Perceptions and Attitudes Regarding Medical Device Development in Canada Among Canadian Innovators: A Qualitative Study
by Ikennah L. Browne & Andrew J. Sutton & Wei Zhang - 811-822 Disease Burden, Treatment Patterns, and Economic Impact of Rectovaginal Fistulas in Patients with Crohn’s Disease: Findings from a Retrospective, Observational, Longitudinal Study Based on US Claims Databases
by Chitra Karki & Dominick Latremouille-Viau & Inmaculada Gilaberte & Gary Hantsbarger & Hela Romdhani & Amy L. Lightner - 823-840 Content Validity and Psychometric Evaluation of the Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT–Fatigue) in Patients with Crohn’s Disease and Ulcerative Colitis
by Edward V. Loftus & Ashwin N. Ananthakrishnan & Wan-Ju Lee & Yuri Sanchez Gonzalez & Kristina A Fitzgerald & Kori Wallace & Wen Zhou & Leighann Litcher-Kelly & Sarah B. Ollis & Sylvia Su & Silvio Danese - 841-849 A Relative Cost of Control Analysis of IDegLira versus Other Forms of Basal Insulin Intensification in Mexico
by Juan Carlos Garnica-Cuellar & Enrique Morales-Villegas & Carmen Alicia López-Forero & Bárbara Monroy-Cruz & Bhrugu Pariti & Swati Deshwal & Manisha Sekharan & Mariana Osorio-Hernández & Ida Caterina García-Appendini - 851-860 Highly Purified Human Menopausal Gonadotropin (HP-hMG) Versus Recombinant Follicle-Stimulating Hormone (rFSH) for Controlled Ovarian Stimulation in US Predicted High-Responder Patients: A Cost-Comparison Analysis
by Andrew Khair & Tray Brown & Marie Markert & Carsten Rødseth Barsøe & Gaurang S. Daftary & Patrick W. Heiser - 861-861 Correction: Cost-Effectiveness Analysis of Antimicrobial Prescribing in the Treatment of Clostridioides Difficile Infection in England
by Tom Bromilow & Hayden Holmes & Laura Coote & Sam Woods & Joshua Pink
July 2023, Volume 7, Issue 4
- 507-523 A Simple Cost-Effectiveness Model of Screening: An Open-Source Teaching and Research Tool Coded in R
by Yi-Shu Lin & James F O’Mahony & Joost Rosmalen - 525-536 Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Rebecca Bresnahan & Rachel Houten & Janette Greenhalgh & Sarah Nevitt & James Mahon & Sophie Beale & Angela Boland & Devarshi Bhattacharyya & Yenal Dundar & Joanne McEntee & Shreyans Gandhi & Nigel Fleeman & Marty Chaplin - 537-552 Cost Effectiveness of Strategies for Caring for Critically Ill Patients with COVID-19 in Tanzania
by Hiral Anil Shah & Tim Baker & Carl Otto Schell & August Kuwawenaruwa & Khamis Awadh & Karima Khalid & Angela Kairu & Vincent Were & Edwine Barasa & Peter Baker & Lorna Guinness - 553-565 Healthcare Payer Perspectives on the Assessment and Pricing of Oncology Multi-Indication Products: Evidence from Nine OECD Countries
by Mackenzie Mills & Panos Kanavos - 567-577 Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland
by Esra Çakar & César Oniangue-Ndza & Ralph P. Schneider & Sven L. Klijn & Ursula M. Vogl & Christian Rothermundt & Jessica R. May - 579-591 Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study
by Ryan Pulleyblank & Nikolaj Birk Larsen - 593-603 Dealing with Time Estimates in Hospital Cost Accounting: Integrating Fuzzy Logic into Time-Driven Activity-Based Costing
by Fiona Koster & Marc R. Kok & Jaco Kooij & Geeke Waverijn & Angelique E. A. M. Weel-Koenders & Deirisa Lopes Barreto - 605-615 Secukinumab in Ankylosing Spondylitis Patients: A Cost-per-Responder Analysis from the Indonesian Health System Perspective
by Cesarius Singgih Wahono & Laniyati Hamijoyo & Yuriawati Hendrawan & Liyana Rakinaturia & Neha Mittal & Prabal Khanna & Minal Jain & Harry Isbagio - 617-626 Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis
by Julie Vanderpoel & Bruno Emond & Isabelle Ghelerter & Katherine Milbers & Marie-Hélène Lafeuille & Patrick Lefebvre & Lorie A. Ellis - 627-638 Estimation of Health Utility Scores for Glycogen Storage Disease Type Ia
by Eliza Kruger & Daniel Aggio & Hayley Freitas & Andrew Lloyd - 639-653 Cost-Effectiveness of Blinatumomab in Pediatric Patients with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia in France
by Megane Caillon & Benoit Brethon & Chrissy Beurden-Tan & Romain Supiot & Antoine Mezo & Jean-Vannak Chauny & Istvan Majer & Arnaud Petit - 655-663 Effect of Perioperative Oral Vitamin C Supplementation on In-Hospital Postoperative Medication Costs for Cardiac Surgery Patients: A Prospective, Single-Centre, Randomised Clinical Trial
by Jan Heerman & Charlotte Boydens & Silvie Allaert & Koen Cathenis & Koen Deryckere & Henk Vanoverschelde - 665-678 Systematic Review and Cost-Consequence Analysis of Ambu aScope 5 Broncho Compared with Reusable Flexible Bronchoscopes: Insights from Two US University Hospitals and an Academic Institution
by Anders E. Kristensen & Jonathan S. Kurman & D. K. Hogarth & Sonali Sethi & Sabrina S. Sørensen
May 2023, Volume 7, Issue 3
- 337-344 Unmet Parenthood Goals, Health-Related Quality of Life and Apparent Irrationality: Understanding the Value of Treatments for Infertility
by Chris Skedgel & Patricia Cubi-Molla & David Mott & Sofia Gameiro & Jacky Boivin & Hareth Al-Janabi & John Brazier & Marie Markert & Fredrik L. Andersson & Mireia Jofre-Bonet - 345-358 Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Rachel Houten & Nigel Fleeman & James Mahon & Marty Chaplin & Katherine Edwards & Sophie Beale & Angela Boland & Yenal Dundar & Ashley Marsden & Zafar Malik & Carlo Palmieri - 359-371 Health Economic Studies of Surfactant Replacement Therapy in Neonates with Respiratory Distress Syndrome: A Systematic Literature Review
by Tiziana Magni & Chiara Ragni & Nicola Pelizzi & Sheetal Sharma & Lucia Perez-Kempner & Erika Turkstra & Jyothsna Nathani & Martina Orlovic & Natalia Meshchenkova - 373-381 The Evaluation of Drug Innovativeness in Italy: Key Determinants and Internal Consistency
by Claudio Jommi & Carlotta Galeone - 383-392 Impact of Extrapolation Model Choices on the Structural Uncertainty in Economic Evaluations for Cancer Immunotherapy: A Case Study of Checkmate 067
by Taihang Shao & Mingye Zhao & Leyi Liang & Lizheng Shi & Wenxi Tang - 393-404 Cost Effectiveness of Letermovir for Cytomegalovirus Prophylaxis Compared with Pre-Emptive Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the United States
by Aryana Sepassi & Ila M. Saunders & Mark Bounthavong & Randy A. Taplitz & Cathy Logan & Jonathan H. Watanabe - 405-416 A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy
by Paolo Angelo Cortesi & Carla Fornari & Paolo Gisondi & Florenzo Iannone & Ippazio Cosimo Antonazzo & Elisabetta Aloisi & Martina Fiocchi & Daniela Ritrovato & Lorenzo Giovanni Mantovani - 417-429 Economic Evaluation Comparing Virtual Reality with Child Life Programming for Non-sedated Pediatric Medical Imaging: A Cost-Consequence Analysis
by John Jacob & Chelsea Stunden & Dhayanand Deenadayalan & Luke Thomas - 431-441 Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain
by A. M. Alonso Torres & A. G. Arévalo Bernabé & N. Becerril Ríos & M. F. Hellín Gil & J. M. Martínez Sesmero & V. Meca Lallana & Ll. Ramió-Torrentà & A. Rodríguez-Antigüedad & L. Gómez Maldonado & I. Triana Junco & M. Gómez-Barrera & N. Espinoza Cámac & I. Oyagüez - 443-454 Economic Evaluation of Tirbanibulin for the Treatment of Actinic Keratosis in Scotland
by Amy Dymond & Will Green & Mary Edwards & Maria Angeles Lopez Pont & Girish Gupta - 455-467 Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer
by Andre Verhoek & Parneet Cheema & Barbara Melosky & Benoit Samson & Frances A. Shepherd & Filippo Marinis & Thomas John & Yi-Long Wu & Bart Heeg & Nadia Dalfsen & Benjamin Bracke & Miguel Miranda & Simon Shaw & Daniel Moldaver - 469-477 Elicitation of Health State Utilities Associated with Progression from Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)
by Owen Alan Edwards Cooper & Ola Ghatnekar & Natalia Piglowska & Charlie A. Smith & Paul Swinburn & James W. F. Catto & Günter Niegisch & Jørn Skibsted Jakobsen - 479-491 Budget Impact of Three Improvement Targets for Compression Therapy for Patients with Deep Venous Thrombosis in The Netherlands
by Rachel H. P. Schreurs & Arina J. Cate-Hoek & Hugo Cate & Manuela A. Joore - 493-505 Cost Analysis of a Transition Care Bundle Compared with Usual Care for COPD Patients Being Discharged from Hospital: Evaluation of a Randomized Controlled Trial
by Charles Yan & Jeff Round & Ilke Akpinar & Chantal E. Atwood & Lesly Deuchar & Mohit Bhutani & Richard Leigh & Michael K. Stickland
March 2023, Volume 7, Issue 2
- 163-173 The Impact of Digital Health Interventions for the Management of Type 2 Diabetes on Health and Social Care Utilisation and Costs: A Systematic Review
by Tiyi Morris & Fiona Aspinal & Jean Ledger & Keyi Li & Manuel Gomes - 175-187 The Challenge for Orphan Drugs Remains: Three Case Studies Demonstrating the Impact of Changes to NICE Methods and Processes and Alternative Mechanisms to Value Orphan Products
by Dawn Lee & Grant McCarthy & Omar Saeed & Rachel Allen & Kinga Malottki & Fleur Chandler - 189-197 Estimating the Incidence-Based Cost of Illness Due to Hematopoietic Stem Cell Transplantation Using One-Year Insurance Claim Data in Korea
by Sol Kwon & Hye-Young Kang - 199-216 A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada
by Anuja Chatterjee & Gijs Wetering & Ron Goeree & Carolyn Owen & Anne Marie Desbois & Stephane Barakat & Beenish S. Manzoor & Kavita Sail - 217-228 Framework for Patient Experience Value Elements in Rare Disease: A Case Study Demonstrating the Applicability of Combined Qualitative and Quantitative Methods
by R. Brett McQueen & Nicholas D. Mendola & Ivett Jakab & Jeffrey Bennett & Kavita V. Nair & Bertalan Németh & András Inotai & Zoltán Kaló - 229-241 Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal
by Paulo Martins & Björn Vandewalle & Jorge Félix & Carlos M. Capela & João J. Cerqueira & António V. Salgado & Diana G. Ferreira & Isabel Monteiro - 243-255 A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States
by Rajiv Mallick & Rashad Carlton & Joris Stiphout - 257-271 Attributable Patient Cost of Antimicrobial Resistance: A Prospective Parallel Cohort Study in Two Public Teaching Hospitals in Ghana
by Evans Otieku & Ama Pokuaa Fenny & Appiah-Korang Labi & Alex Owusu Ofori & Joergen Anders Lindholm Kurtzhals & Ulrika Enemark - 273-284 Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China
by Shanlian Hu & Zhiliu Tang & James P. Harrison & Nadine Hertel & John R. Penrod & Jessica R. May & Ariadna Juarez-Garcia & Orban Holdgate - 285-298 Cost-Utility Analysis of the Caresyntax Platform to Identify Patients at Risk of Surgical Site Infection Undergoing Colorectal Surgery
by Eoin Moloney & Atefeh Mashayekhi & Mehdi Javanbakht & Mohsen Rezaei Hemami & Michael Branagan-Harris - 299-312 The Burden of Caring for Individuals with Tuberous Sclerosis Complex (TSC) Who Experience Epileptic Seizures: A Descriptive UK Survey
by Hanna Skrobanski & Kishan Vyas & Sally Bowditch & Lena Hubig & Edward Dziadulewicz & Louise Fish & Pooja Takhar & Siu Hing Lo - 313-320 A Framework for a Health Economic Evaluation Model for Patients with Sickle Cell Disease to Estimate the Value of New Treatments in the United States of America
by Aaron Winn & Anirban Basu & Scott D. Ramsey - 321-335 The Cost-Effectiveness of a Dance and Yoga Intervention for Girls with Functional Abdominal Pain Disorders
by Anna Philipson & Anna Duberg & Lars Hagberg & Sofie Högström & Lars Lindholm & Margareta Möller & Linda Ryen
January 2023, Volume 7, Issue 1
- 3-36 A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting
by Conor McCloskey & María Toboso Ortega & Sunita Nair & Maria João Garcia & Federico Manevy - 37-46 Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial
by F. Felizzi & Aino Launonen & P.-O. Thuresson - 47-48 Correction to: Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial
by F. Felizzi & Aino Launonen & P.-O. Thuresson - 49-62 Cost Effectiveness of Ambulatory Blood Pressure Monitoring Compared with Home or Clinic Blood Pressure Monitoring for Diagnosing Hypertension in Australia
by Karan K. Shah & Melina Willson & Blaise Agresta & Rachael L. Morton - 63-63 Correction to: Cost Effectiveness of Ambulatory Blood Pressure Monitoring Compared with Home or Clinic Blood Pressure Monitoring for Diagnosing Hypertension in Australia
by Karan K. Shah & Melina Willson & Blaise Agresta & Rachael L. Morton - 65-76 Estimating the Economic and Clinical Value of Introducing Ceftazidime/Avibactam into Antimicrobial Practice in Japan: A Dynamic Modelling Study
by Tetsuya Matsumoto & Akira Yuasa & Ryan Miller & Clive Pritchard & Takahisa Ohashi & Amer Taie & Jason Gordon - 77-91 “Don’t Think Twice, It’s All Right”: Using Additional Data to Reduce Uncertainty Regarding Oncologic Drugs Provided Through Managed Access Agreements in England
by Jiyeon Kang & John Cairns - 93-110 Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis
by Mehdi Javanbakht & Jesse Fishman & Eoin Moloney & Peter Rydqvist & Amir Ansaripour - 111-120 Healthcare Costs Before and After Diagnosis of Cancer of Unknown Primary Versus Ovarian Cancer in Australia
by Louisa G. Gordon & C. Wood & R. W. Tothill & P. M. Webb & P. Schofield & L. Mileshkin - 121-138 Psychometric Validation of the Growth Hormone Deficiency–Child Treatment Burden Measure (GHD-CTB) and the Growth Hormone Deficiency–Parent Treatment Burden Measure (GHD-PTB)
by Meryl Brod & Michael Højby Rasmussen & Suzanne Alolga & Jane F. Beck & Donald M. Bushnell & Kai Wai Lee & Aristides Maniatis - 139-148 Mapping of the World Health Organization Quality of Life Brief (WHOQOL-BREF) to the EQ-5D-5L in the General Thai Population
by Krittaphas Kangwanrattanakul - 149-161 Mapping the Insomnia Severity Index Instrument to EQ-5D Health State Utilities: A United Kingdom Perspective
by François-Xavier Chalet & Teodora Bujaroska & Evi Germeni & Nizar Ghandri & Emilio T. Maddalena & Kushal Modi & Abisola Olopoenia & Jeffrey Thompson & Matteo Togninalli & Andrew H. Briggs
November 2022, Volume 6, Issue 6
- 773-786 Cost-Effectiveness Analyses of Lung Cancer Screening Using Low-Dose Computed Tomography: A Systematic Review Assessing Strategy Comparison and Risk Stratification
by Matthew Fabbro & Kirah Hahn & Olivia Novaes & Mícheál Ó’Grálaigh & James F. O’Mahony - 787-797 The Cost of Flexible Bronchoscopes: A Systematic Review and Meta-analysis
by Carina Østervig Andersen & Helena Travis & Emilie Dehlholm-Lambertsen & Rasmus Russell & Emmelie Ploug Jørgensen - 799-809 Implications of Payment for Acute Myocardial Infarctions as a 90-Day Bundled Single Episode of Care: A Cost of Illness Analysis
by Keith B. Allen & James E. Alexander & Joshua N. Liberman & Susan Gabriel - 811-822 Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
by David Elsea & Lin Fan & Adela Mihai & Fadoua El Moustaid & Daniel Simmons & Matthew Monberg & Dominic Muston - 823-836 An EQ-5D-5L Value Set for Belgium
by Nicolas Bouckaert & Irina Cleemput & Stephan Devriese & Sophie Gerkens - 837-846 Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia
by Fabio Gil & Fabian Juliao-Baños & Luisa Amador & Natalia Castano & Juan Manuel Reyes - 847-857 What is the Economic Cost of Providing an All Wales Postpartum Haemorrhage Quality Improvement Initiative (OBS Cymru)? A Cost-Consequences Comparison with Standard Care
by Megan Dale & Sarah F Bell & Susan O’Connell & Cerys Scarr & Kathryn James & Miriam John & Rachel E Collis & Peter W Collins & Grace Carolan-Rees - 859-870 Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
by Moogeh Baharnoori & Virender Bhan & Fraser Clift & Kimberly Thomas & Soukaïna Mouallif & Nicholas Adlard & Philip Cooney & François Blanchette & Barkha P. Patel & Daniel Grima - 871-880 Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months
by Andrew Blauvelt & Nianwen Shi & Russel Burge & Bilal Atiya & Baojin Zhu & Najwa Somani & Terri Ridenour & Carolyn R. Lew & Nicole M. Zimmerman & Mwangi J. Murage - 881-892 Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin
by Holly Cranmer & David Trueman & Elise Evers & Fionn Woodcock & Tanja Podkonjak - 893-895 Should Drug Companies Engage with ICER? An Empirical Analysis of How Often Manufacturers Engage with ICER and Whether Engagement May Influence ICER’s Cost-Effectiveness Estimates
by Rachel Milstein Breslau & Joshua T. Cohen & Daniel A. Ollendorf & Peter J. Neumann - 897-897 Correction to: Implications of Payment for Acute Myocardial Infarctions as a 90-Day Bundled Single Episode of Care: A Cost of Illness Analysis
by Keith B. Allen & James E. Alexander & Joshua N. Liberman & Susan Gabriel - 899-899 Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
by David Elsea & Lin Fan & Adela Mihai & Fadoua El Moustaid & Daniel Simmons & Matthew Monberg & Dominic Muston
September 2022, Volume 6, Issue 5
- 631-635 Using Health Economics to Inform Immunization Policy Across All Levels of Government
by Ellen Rafferty & Laura Reifferscheid & Ali Assi & Shannon E. MacDonald - 637-646 How are Companion Diagnostics Considered in Economic Evaluations of Oncology Treatments? A Review of Health Technology Assessments
by Melissa Gomez Montero & Houcine El Alili & Mahmoud Hashim & Peter Wigfield & Mariya Dimova & Ralph Riley & Katie Pascoe - 647-656 Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
by Lotte Westerink & Jelmer Lennart Jens Nicolai & Maarten Jacobus Postma & Job Frank Martien Boven & Cornelis Boersma - 657-668 Cost-Utility and Budget Impact Analysis of Implementing Anticoagulation Clinics and Point-of-Care Monitoring Devices in Anticoagulated Patients in Argentina
by Osvaldo Ulises Garay & Gonzalo Guiñazú & Yolanda Patricia Adamczuk & Cristina Duboscq - 669-679 Public Preferences and Willingness to Pay for a COVID-19 Vaccine in Iran: A Discrete Choice Experiment
by Alireza Darrudi & Rajabali Daroudi & Masud Yunesian & Ali Akbari Sari - 681-696 Cost-Effectiveness Analysis of a Medial Meniscus Replacement Prosthesis for the Treatment of Patients with Medial Compartment Pain in the United Kingdom
by Mehdi Javanbakht & Atefeh Mashayekhi & Angeline Carlson & Eoin Moloney & Martyn Snow & James Murray & Tim Spalding - 697-710 Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067
by Timothy Baker & Helen Johnson & Srividya Kotapati & Andriy Moshyk & Melissa Hamilton & Murat Kurt & Victoria Federico Paly - 711-721 The Physician and Administrator-Reported Cost of Drug Utilization Management to Physician Practices: A Cross-Sectional Survey
by Marie Louise Edwards & Perry T. Yin & Michael Kuehn & Keith Bratti & Noam Kirson & Anupam Jena & Scott Howell - 723-733 Cost-Utility Analysis of Planned Early Delivery or Expectant Management for Late Preterm Pre-eclampsia (PHOENIX)
by Rachael Hunter & Alice Beardmore-Gray & Melanie Greenland & Louise Linsell & Edmund Juszczak & Pollyanna Hardy & Anna Placzek & Andrew Shennan & Neil Marlow & Lucy C. Chappell - 735-743 Budget Impact of Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF) and Iron Deficiency in Switzerland
by Elisabeth Brock & Giorgio Moschovitis & Micha T. Maeder & Otmar Pfister - 745-756 Cost of Surgical Care at Public Sector District Hospitals in India: Implications for Universal Health Coverage and Publicly Financed Health Insurance Schemes
by Maninder Pal Singh & Shankar Prinja & Kavitha Rajsekar & Praveen Gedam & Vipul Aggarwal & Oshima Sachin & Jyotsna Naik & Ajai Agarwal & Sanjay Kumar & Setu Sinha & Varsha Singh & Prakash Patel & Amit C. Patel & Rajendra Joshi & Avijit Hazra & Raghunath Misra & Divya Mehrotra & Sashi Bhusan Biswal & Ankita Panigrahy & Kusum Lata Gaur & Jai Prakash Pankaj & Dharmesh Kumar Sharma & Kondeti Madhavi & Pulaganti Madhusudana & K. Narayanasamy & A. Chitra & Gajanan D. Velhal & Amit S. Bhondve & Rakesh Bahl & Amit Sachdeva & Sharminder Kaur & Anu Nagar & Balram Bhargava - 757-771 The Cost Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease with and without Heart Failure in Ireland
by Thomas Ward & Tray Brown & Ruth D. Lewis & Melodi Kosaner Kliess & Antonio Ramirez Arellano & Carol M. Quinn
July 2022, Volume 6, Issue 4
- 469-481 Medical and Non-medical Costs of Sickle Cell Disease and Treatments from a US Perspective: A Systematic Review and Landscape Analysis
by Zachary Baldwin & Boshen Jiao & Anirban Basu & Joshua Roth & M. A. Bender & Zizi Elsisi & Kate M. Johnson & Emma Cousin & Scott D. Ramsey & Beth Devine - 483-494 Cost Effectiveness of Patient Self-Managed Warfarin Compared with Direct Oral Anticoagulants in Atrial Fibrillation: An Economic Evaluation in a Danish Healthcare Sector Setting
by Sabine Michelsen Raunbak & Anne Sig Sørensen & Louise Hansen & Flemming Skjøth & Torben Bjerregaard Larsen & Lars Holger Ehlers - 495-507 Costs and Effects of Implementing Digital Tomosynthesis in a Population-Based Breast Cancer Screening Program: Predictions Using Results from the To-Be Trial in Norway
by Tron Anders Moger & Åsne Holen & Berit Hanestad & Solveig Hofvind - 509-518 Direct Medical Costs of Four Vaccine-Preventable Infectious Diseases in Older Adults in Spain
by Ángel Gil de Miguel & José María Eiros Bouza & Luis Ignacio Martínez Alcorta & Daniel Callejo & Carlos Miñarro & Laura Amanda Vallejo-Aparicio & Andrea García & Mónica Tafalla & María del Rosario Cambronero & Rubén Rodríguez & Laura Martin-Gomez - 519-537 Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada
by Elisabetta Fenu & Vasily Lukyanov & Annabel Acs & Xenia Radu & Stephanie Stypa & Aren Fischer & John K. Marshall & Mark Oppe - 539-548 Differences in Breast Cancer Costs by Cancer Stage and Biomarker Subtype in New Zealand
by Chunhuan Lao & Mohana Mondal & Marion Kuper-Hommel & Ian Campbell & Ross Lawrenson - 549-562 Cost-Effectiveness Analysis of Intravascular Targeted Temperature Management after Cardiac Arrest in England
by Mehdi Javanbakht & Atefeh Mashayekhi & Mohsen Rezaei Hemami & Michael Branagan-Harris & Thomas R Keeble & Mohsen Yaghoubi - 563-574 Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument
by Matthew Reaney & Veleka Allen & Amy J. Sehnert & Liang Fang & Albert A. Hagège & Srihari S. Naidu & Iacopo Olivotto - 575-586 Longitudinal Psychometric Analysis of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ) Using Outcomes from the Phase III EXPLORER-HCM Trial
by Matthew Reaney & Prithvi Addepalli & Veleka Allen & John A. Spertus & Chantal Dolan & Amy J. Sehnert & Jennifer T. Fine - 587-594 Cost Analysis of Adjuvant Whole-Brain Radiotherapy Treatment Versus No Whole-Brain Radiotherapy After Stereotactic Radiosurgery and/or Surgery Among Adults with One to Three Melanoma Brain Metastases: Results from a Randomized Trial
by Anh Dam Tran & Angela M. Hong & Mai T. H. Nguyen & Gerald Fogarty & Victoria Steel & Elizabeth Paton & Rachael L. Morton - 595-603 Feasibility of Deriving Health State Utilities in Mycosis Fungoides Cutaneous T-Cell Lymphoma Using Mapping Algorithms
by Michela Meregaglia & Rosanna Tarricone - 605-617 Economic Evaluation of Using Daily Prednisolone versus Placebo at the Time of an Upper Respiratory Tract Infection for the Management of Children with Steroid-Sensitive Nephrotic Syndrome: A Model-Based Analysis
by Nafsika Afentou & Emma Frew & Samir Mehta & Natalie J. Ives & Rebecca L. Woolley & Elizabeth A. Brettell & Adam R. Khan & David V. Milford & Detlef Bockenhauer & Moin A. Saleem & Angela S. Hall & Ania Koziell & Heather Maxwell & Shivaram Hegde & Eric Finlay & Rodney D. Gilbert & Caroline Jones & Karl McKeever & Wendy Cook & Nicholas J. A. Webb & Martin T. Christian - 619-628 Healthcare Resource Utilization and Cost of Patients with Multiple Myeloma in Germany: A Retrospective Claims Data Analysis
by Zeki Kocaata & Thomas Wilke & Franz Fischer & Robert Welte & Hermann Einsele - 629-629 Correction to: Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries
by Anna-Maria Fontrier & Erica Visintin & Panos Kanavos
May 2022, Volume 6, Issue 3
- 315-328 Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries
by Anna-Maria Fontrier & Erica Visintin & Panos Kanavos - 329-342 Community Distribution of Naloxone: A Systematic Review of Economic Evaluations
by Nelda Cherrier & Joanne Kearon & Robin Tetreault & Sophiya Garasia & Emmanuel Guindon - 343-354 Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting
by Björn Eliasson & Åsa Ericsson & Adam Fridhammar & Andreas Nilsson & Sofie Persson & Barrie Chubb - 355-365 A Cost-Utility Analysis of Trabecular Bypass Devices Versus Usual Care for Patients With Open-Angle Glaucoma
by Paul R. Healey & Dominic Tilden & Dan Jackson & Lara Aghajanian - 367-376 Health State Utilities for Adverse Events Associated with Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma
by Timothy A. Howell & Louis S. Matza & Monika P. Jun & Jacob Garcia & Annette Powers & David G. Maloney - 377-388 Cost Effectiveness of Digital Interventions for Generalised Anxiety Disorder: A Model-Based Analysis
by Dina Jankovic & Pedro Saramago Goncalves & Lina Gega & David Marshall & Kath Wright & Meena Hafidh & Rachel Churchill & Laura Bojke - 389-403 An Economic Evaluation Supported by Qualitative Data About the Patient Concerns Inventory (PCI) versus Standard Treatment Pathway in the Management of Patients with Head and Neck Cancer
by Victory ‘Segun Ezeofor & Llinos Haf Spencer & Simon N. Rogers & Anastasios Kanatas & Derek Lowe & Cherith J. Semple & Jeffrey R. Hanna & Seow Tien Yeo & Rhiannon Tudor Edwards - 405-414 Prevalence and Cost of Care for Parkinson’s Disease in Luxembourg: An Analysis of National Healthcare Insurance Data
by Susanne Schmitz & Michel Vaillant & Christell Renoux & Robert L. Konsbruck & Pierre Hertz & Magali Perquin & Lukas Pavelka & Rejko Krüger & Laetitia Huiart - 415-424 Epidemiologic and Economic Analysis of Rapid Antiretroviral Therapy Initiation with Bictegravir/Emtricitabine/Tenofovir Alafenamide in Spain
by Vicente Estrada & Miguel Górgolas & José A. Peña & Elena Tortajada & Antonio Castro & María Presa & Itziar Oyagüez - 425-435 Examining the Association between Polish Migrant Status and Health Preferences Using a Novel Application of a Smaller Design EQ-5D-5L Valuation Study
by Dan Kelleher & Samer Kharroubi & Edel Doherty & Gianluca Baio & Ciaran O’Neill - 437-450 Cost-Effectiveness of Constraint-Induced Movement Therapy Implementation in Neurorehabilitation: The ACTIveARM Project
by Lauren J. Christie & Nicola Fearn & Annie McCluskey & Meryl Lovarini & Reem Rendell & Alison Pearce - 451-460 Cost Savings of Mother’s Own Milk for Very Low Birth Weight Infants in the Neonatal Intensive Care Unit
by Tricia J. Johnson & Aloka L. Patel & Michael E. Schoeny & Paula P. Meier - 461-468 Stage-Related Cost of Treatment of Bladder Cancer in Brazil
by Fernando Korkes & Frederico Timóteo & Luiza C. B. Soledade & Lara S. Bugalho & Guilherme A. Peixoto & Vanessa D. Teich & Sidney Glina
March 2022, Volume 6, Issue 2
- 137-145 Impact of a New Cost-Effectiveness Threshold Implementation on Cancer Formulary Decisions in Jordan
by Imad Treish & Abeer Al Rabayah & Saad Jaddoua & Haitham Tuffaha - 147-167 Evaluation of Advanced Therapy Medicinal Products by the National Institute for Health and Care Excellence (NICE): An Updated Review
by Ana-Catarina Pinho-Gomes & John Cairns - 169-178 Budget Impact of the Vest™ High Frequency Chest Wall Oscillation System for Managing Airway Clearance in Patients with Complex Neurological Disorders: A US Healthcare Payers’ Perspective Analysis
by Amir Ansaripour & Kari Roehrich & Atefeh Mashayekhi & Mwanamisi Wanjala & Shani Noel & Mohsen Rezaei Hemami & Angela Murray & Mehdi Javanbakht - 179-192 Cost Effectiveness of Internet-Delivered Acceptance and Commitment Therapy for Patients with Severe Health Anxiety: A Randomised Controlled Trial
by Bettina Wulff Risør & Ditte Hoffmann Frydendal & Marie Konge Villemoes & Camilla Palmhøj Nielsen & Charlotte Ulrikka Rask & Lisbeth Frostholm - 193-210 Examining Ways to Improve Weight Control Programs’ Population Reach and Representativeness: A Discrete Choice Experiment of Financial Incentives
by Wen You & Yuan Yuan & Kevin J. Boyle & Tzeyu L. Michaud & Chris Parmeter & Richard W. Seidel & Paul A. Estabrooks - 211-218 Cost of Illness in Patients with Duchenne Muscular Dystrophy in Portugal: The COIDUCH Study
by Pedro Labisa & Valeska Andreozzi & Melina Mota & Susana Monteiro & Rita Alves & João Almeida & Björn Vandewalle & Jorge Felix & Katharina Buesch & Hugo Canhão & Igor Beitia Ortiz de Zarate - 219-229 Delineating the Type 2 Diabetes Population in the Netherlands Using an All-Payer Claims Database: Specialist Care, Medication Utilization and Expenditures 2016–2018
by Rose J. Geurten & Jeroen N. Struijs & Arianne M. J. Elissen & Henk J. G. Bilo & Chantal Tilburg & Dirk Ruwaard - 231-239 Time Trade-Off Utilities for Hereditary Angioedema Health and Caregiver States
by Siu Hing Lo & Andrew Lloyd & Shuayb Elkhalifa & Zlatko Sisic & Floortje E. Nooten - 241-252 Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective
by Will Dunlop & Marjolijn Keep & Peter Elroy & Ignacio Diaz Perez & Mario J. N. M. Ouwens & Tina Sarbajna & Yiduo Zhang & Alastair Greystoke - 253-263 Budget Impact Analysis of an Epigenetic Test Used for Diagnosing Fetal Alcohol Spectrum Disorder from the Perspective of a Laboratory Budget Holder in Manitoba, Canada
by Patrick Berrigan & Geoffrey G. Hicks & Wendy J. Ungar & Jennifer D. Zwicker - 265-275 The Societal Economic Impact of Secukinumab in First-Line Treatment of Moderate to Severe Plaque Psoriasis in Germany: An Open-Cohort Simulation
by Ahmed H. Seddik & Nima Melzer & Foteini Tsotra & Dennis A. Ostwald - 277-291 Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia
by Ahmed Alghamdi & Bander Balkhi & Abdulaziz Altowaijri & Nasser Al-shehri & Lewis Ralph & Emily-Ruth Marriott & Michael Urbich & Fawaz Aljanad & Rima Aziziyeh - 293-302 Real-World Treatment Patterns, Outcomes, Resource Utilization and Costs in Treatment-Resistant Major Depressive Disorder: PATTERN, a Retrospective Cohort Study in Belgium
by B. Gillain & G. Degraeve & T. Dreesen & G. De Bruecker & E. Buntinx & D. Beke & C. Kestens & E. Valassopoulou & F. Verhelst & E. Peeters & S. Pype & C. De Vos & D. Strens & I. Vandersmissen - 303-313 Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
by Dikshyanta Rana & Claudia Geue & Kelly Baillie & Jiafeng Pan & Tanja Mueller & Jennifer Laskey & Marion Bennie & Julie Clarke & Robert J. Jones & Ailsa Brown & Olivia Wu
January 2022, Volume 6, Issue 1
- 5-8 NICE and the EQ-5D-5L: Ten Years Trouble
by Chris Sampson - 9-19 A Systematic Review of Cost-Effectiveness Analyses for Hepatocellular Carcinoma Treatment
by Sydney C. Yuen & Adaeze Q. Amaefule & Hannah H. Kim & Breanna-Verissa Owoo & Emily F. Gorman & T. Joseph Mattingly - 21-32 The Utility of Economic Measures to Quantify the Burden of Tinnitus in Affected Individuals: A Scoping Review
by Elza Daoud & Charlotte Caimino & Michael A. Akeroyd & Arnaud J. Noreña & David M. Baguley - 33-45 Cost-Effectiveness Analysis of the Treatment Strategies with or without Opioid Medications in Surgery-Eligible Patients with Osteoarthritis in Japan
by Tomoyuki Takura & Akira Yuasa & Naohiro Yonemoto & Sven Demiya & Hiroyuki Matsuda & Nozomi Ebata & Koichi Fujii & Muneaki Ishijima - 47-62 Cost-Effectiveness of Inotuzumab Ozogamicin Compared to Standard of Care Chemotherapy for Treating Relapsed or Refractory Acute Lymphoblastic Leukaemia Patients in Norway and Sweden
by I. Oostrum & T. A. Russell-Smith & M. Jakobsson & J. Torup Østby & B. Heeg - 63-72 A Real-World Assessment of Outcomes, Health Resource Utilization, and Costs Associated with Cerebral Edema in US Patients with Large Hemispheric Infarction
by Nicole Tsao & Qiang Hou & Shih-Yin Chen & Steven R. Messe - 73-83 Continuous Monitoring of Respiratory Rate with Wearable Sensor in Patients Admitted to Hospital with Pneumonia Compared with Intermittent Nurse-Led Monitoring in the United Kingdom: A Cost-Utility Analysis
by Mehdi Javanbakht & Maziar Moradi-Lakeh & Atefeh Mashayekhi & Jowan Atkinson - 85-94 Cost Effectiveness of a Cultural Physical Activity Intervention to Reduce Blood Pressure Among Native Hawaiians with Hypertension
by Ashley F. Railey & Clemma Muller & Carolyn Noonan & Maureen Schmitter-Edgecombe & Ka’imi Sinclair & Corin Kim & Mele Look & J. Keawe‘aimoku Kaholokula - 95-104 Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy
by Massimiliano Bonifacio & Vikalp Maheshwari & Diana Tran & Gianluca Agostoni & Kalitsa Filioussi & Ricardo Viana - 105-121 Patient and Caregiver Health State Utilities in Tuberous Sclerosis Complex
by Siu Hing Lo & Jade Marshall & Hanna Skrobanski & Andrew Lloyd - 123-135 Economic Analysis of the CADScor System for Ruling Out Coronary Artery Disease in England
by Mehdi Javanbakht & Atefeh Mashayekhi & Mohsen Rezaei Hemami & Michael Branagan-Harris & Eoin Moloney
December 2021, Volume 5, Issue 4
- 561-576 Evidence-Based Medicine and Healthcare Quality in the Context of Information Failure: The Case of the UK Fertility Sector
by Minyan Zhu - 577-586 gammaCore for Cluster Headaches: A NICE Medical Technologies Guidance
by Susan O’Connell & Megan Dale & Helen Morgan & Kimberley Carter & Rhys Morris & Grace Carolan-Rees - 587-603 Inclusion of Additional Unintended Consequences in Economic Evaluation: A Systematic Review of Immunization and Tuberculosis Cost-Effectiveness Analyses
by Liv Solvår Nymark & Alex Miller & Anna Vassall - 605-612 Criteria and Scoring Functions Used in Multi-criteria Decision Analysis and Value Frameworks for the Assessment of Rare Disease Therapies: A Systematic Literature Review
by Tamás Zelei & Nicholas D. Mendola & Baher Elezbawy & Bertalan Németh & Jonathan D. Campbell - 613-623 Hospital Costs of Extracorporeal Membrane Oxygenation in Adults: A Systematic Review
by Annemieke Oude Lansink-Hartgring & Olivier van Minnen & Karin M. Vermeulen & Walter M. van den Bergh - 625-633 Cost-Effectiveness Analysis of rFVIIIFc Versus Contemporary rFVIII Treatments for Patients with Severe Hemophilia A Without Inhibitors in the United States
by Ash Bullement & Emma S. Knowles & Pronabesh DasMahapatra & Talaha Ali & Ron Preblick - 635-647 A Model-Based Economic Evaluation of Cladribine Versus Alemtuzumab, Ocrelizumab and Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis with High Disease Activity in Chile
by Manuel Antonio Espinoza & Rubén Rojas & Alessandro Zaupa & Carlos Balmaceda - 649-653 Smoking Cessation Pharmacotherapy Utilization and Costs to a Medicaid Managed Care Plan
by Robin L. Corelli & Thanh G. Tu & Kyoung J. Lee & Drake Dinh & Kristin R. Gericke & Karen Suchanek Hudmon - 655-664 Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia
by Yared Belete Belay & Eskinder Eshetu Ali & Karen Y. Chung & Gebremedhin Beedemariam Gebretekle & Beate Sander - 665-675 Impact of Including Carer Information in Time Trade-Off Tasks: Results from a Pilot Study
by David J. Mott & Iain Leslie & Koonal Shah & Jennifer Rowell & Nicolas Scheuer - 677-691 Cost Effectiveness of Gemtuzumab Ozogamicin in the First-Line Treatment of Acute Myeloid Leukaemia in the UK
by T. Alexander Russell-Smith & James Brockbank & Carla Mamolo & Christopher Knight - 693-700 Cost-Effectiveness of Peer-Educator–Delivered Lifestyle Modification for Type 2 Diabetes Prevention in a Young Healthy Population in Sri Lanka: A Trial-Based Economic Evaluation and Economic Model
by James Shearer & Miral Kalyani & Anastasios Mangelis & Dileep Silva & Padmal Silva & Mahen Wijesuriya & Janaka Karalliedde - 701-713 Non-Price-Related Determinants of Value and Access for Novel Non-small Cell Lung Cancer Treatments: A Cross-Country Review of HTA Decision Making
by Jason Gordon & Angela Stainthorpe & Beverley Jones & Ian Jacob & Nadine Hertel & Jose Diaz & Yong Yuan & John Borrill - 715-725 Estimation of Health-Related Utilities for 177Lu-DOTATATE in GEP-NET Patients Using Utilities Mapped from EORTC QLQ-C30 to EQ-5D-3L and QLU-C10D Utilities
by Ioana-Alexandra Soare & Oscar Leeuwenkamp & Louise Longworth - 727-736 The Costs and Healthcare Resource Utilization Associated with Anticholinergic Burden in Long-Stay Nursing Home Residents with Overactive Bladder in the US
by Satabdi Chatterjee & David Walker & Tomomi Kimura & Rajender R. Aparasu - 737-753 Economic Evaluation of Transperineal versus Transrectal Devices for Local Anaesthetic Prostate Biopsies
by Edward C. F. Wilson & Alice Wreford & Priya Tamer & Kelly Leonard & Hannah Brechka & Vincent J. Gnanapragasam - 755-764 Direct and Indirect Costs of Non-surgical Treatment for Acute Tonsillitis in Children in Southeast Nigeria
by Maduka Donatus Ughasoro & James Onuorah Akpeh & Nneamaka Echendu & Somkene Okpala & Nneka Getrude Mgbachi & Ogochukwu Chinelo Okanya & Obinna Emmanuel Onwujekwe - 765-778 Cost-Minimization Analysis of Pembrolizumab Monotherapy Versus Nivolumab in Combination with Ipilimumab as First-Line Treatment for Metastatic PD-L1-Positive Non-small Cell Lung Cancer: A US Payer Perspective
by Nan Qiao & Ralph Insinga & Thomas Burke & Gilberto Lopes